Literature DB >> 34176010

Study of visual acuity and contrast sensitivity in diabetic patients with and without non-proliferative diabetic retinopathy.

Teresa Lupión Durán1, Antonio García-Ben2, Verónica Rodríguez Méndez3, Luís Gálvez Alcázar4, Emma García-Ben5, José Manuel García-Campos6.   

Abstract

PURPOSE: To analyze high and low contrast visual acuity and contrast sensitivity in diabetic patients without clinically significant macular edema associated or not with non-proliferative diabetic retinopathy.
METHODS: Cross-sectional study of 368 eyes of 368 patients classified into three groups: a) disease-free patients, b) patients with diabetes mellitus (DM) without diabetic retinopathy, c) DM patients with non-proliferative diabetic retinopathy. All patients underwent a complete ophthalmological examination that included high and low contrast visual acuity with 1.25%, 2.5% and 5% contrast chart and Pelli-Robson type contrast sensitivity test.
RESULTS: We observed no statistically significant differences regarding age, intraocular pressure, duration of diabetes or high contrast visual acuity. The eyes of patients with non-proliferative diabetic retinopathy had worse contrast sensitivity (p = 0.03, in both cases) and low contrast visual acuity at 1.5% (p = 0.03 and p = 0.01), 2.5% (p = 0.01, in both cases) and 5% (p = 0.02 and p = 0.04) than patients free of disease or without diabetic retinopathy.
CONCLUSIONS: Analysis of contrast sensitivity and low contrast visual acuity could be considered as markers of visual function impairment in the eyes of patients with non-proliferative diabetic retinopathy.

Entities:  

Keywords:  Contrast sensitivity; Diabetic retinopathy; High contrast visual acuity; Low contrast visual acuity; Visual acuity

Year:  2021        PMID: 34176010     DOI: 10.1007/s10792-021-01930-x

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  1 in total

1.  Contrast sensitivity loss is coupled with capillary dropout in patients with diabetes.

Authors:  O Arend; A Remky; D Evans; R Stüber; A Harris
Journal:  Invest Ophthalmol Vis Sci       Date:  1997-08       Impact factor: 4.799

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.